Ollin Biosciences raises $330M Series B to fund eye disease trials Jun 24, 2026 08:00PM
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Jun 24, 2026 08:00PM
Ollin Biosciences raises $330M Series B for eye disease drug trials Jun 24, 2026 07:01AM
Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026 Jun 24, 2026 07:00AM